A cannabis-derived drug developed by Germany's Vertanical has shown efficacy in phase 3 as a treatment for chronic pain, offering the prospect of an alternative to opioid drugs that carry the risk of ...

Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed ...

Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb's ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

GSK just hit one of its main objectives for 2025 after getting FDA approval of anti-IL-5 antibody Nucala as a treatment for chronic obstructive pulmonary disease (COPD). Nucala (mepolizumab) has been ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Almost 30,000 people in England with chronic obstructive pulmonary disease (COPD) could soon have access to a biologic treatment, Sanofi and Regeneron's Dupixent, after it was recommended for use by ...

Eli Lilly's injectable GLP-1 agonist medicines for obesity and diabetes drove 56% growth in first-quarter sales, but ...

New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate ...

New guidance from reimbursement authority NICE has recommended Rystiggo (rozanolixizumab) for people with gMG who test ...

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, after Norgine's ...